Ident. | Authors (with country if any) | Title |
---|
000034 |
Stéphane Palfi [France] ; Jean Marc Gurruchaga [France] ; G. Scott Ralph [Royaume-Uni] ; Helene Lepetit [France] ; Sonia Lavisse [France] ; Philip C. Buttery [Royaume-Uni] ; Colin Watts [Royaume-Uni] ; James Miskin [Royaume-Uni] ; Michelle Kelleher [Royaume-Uni] ; Sarah Deeley [Royaume-Uni] ; Hirokazu Iwamuro [France] ; Jean Pascal Lefaucheur [France] ; Claire Thiriez [France] ; Gilles Fenelon [France] ; Cherry Lucas [Royaume-Uni] ; Pierre Brugieres [France] ; Inanna Gabriel [France] ; Kou Abhay [France] ; Xavier Drouot [France] ; Naoki Tani [France] ; Aurelie Kas [France] ; Bijan Ghaleh [France] ; Philippe Le Corvoisier [France] ; Patrice Dolphin [France] ; David P. Breen [Royaume-Uni] ; Sarah Mason [Royaume-Uni] ; Natalie Valle Guzman [Royaume-Uni] ; Nicholas D. Mazarakis [Royaume-Uni] ; Pippa A. Radcliffe [Royaume-Uni] ; Richard Harrop [Royaume-Uni] ; Susan M. Kingsman [Royaume-Uni] ; Olivier Rascol [France] ; Stuart Naylor [Royaume-Uni] ; Roger A. Barker [Royaume-Uni] ; Philippe Hantraye [France] ; Philippe Remy [France] ; Pierre Cesaro [France] ; Kyriacos A. Mitrophanous [Royaume-Uni] | Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1/2 trial |
000083 |
Santiago Perez-Lloret [France, Argentine] ; Maria Veronica Rey [France] ; Pietro Lucca Ratti [France] ; Olivier Rascol [France] | Rotigotine transdermal patch for the treatment of Parkinson's Disease |
000187 |
Andrew Lees [Royaume-Uni] ; Stanley Fahn [États-Unis] ; Karla M. Eggert [Allemagne] ; Joseph Jankovic [États-Unis] ; Anthony Lang [Canada] ; Federico Micheli [Argentine] ; M. Maral Mouradian [États-Unis] ; Wolfgang H. Oertel [Allemagne] ; C. Warren Olanow [États-Unis] ; Werner Poewe [Autriche] ; Olivier Rascol [France] ; Eduardo Tolosa [Espagne] ; David Squillacote [États-Unis] ; Dinesh Kumar [États-Unis] | Perampanel, an AMPA Antagonist, Found to Have No Benefit in Reducing "Off" Time in Parkinson's Disease |
000351 |
Emmanuelle Bondon-Guitton [France] ; Santiago Perez-Lloret [France] ; Haleh Bagheri [France] ; Christine Brefel [France] ; Olivier Rascol [France] ; Jean-Louis Montastruc [France] | Drug-Induced Parkinsonism: A Review of 17 Years' Experience in a Regional Pharmacovigilance Center in France |
000452 |
Karla Eggert [Allemagne] ; David Squillacote [États-Unis] ; Paolo Barone [Italie] ; Richard Dodel [Allemagne] ; Regina Katzenschlager [Autriche] ; Murat Emre [Turquie] ; Andrew J. Lees [Royaume-Uni] ; Olivier Rascol [France] ; Werner Poewe [Autriche] ; Eduardo Tolosa [Espagne] ; Claudia Trenkwalder [Allemagne] ; Marco Onofrj [Italie] ; Fabrizio Stocchi [Italie] ; Giuseppe Nappi [Italie] ; Vladimir Kostic [Serbie] ; Jagoda Potic [Serbie] ; Evzen Ruzicka [République tchèque] ; Wolfgang Oertel [Allemagne] | Safety and Efficacy of Perampanel in Advanced Parkinson's Disease: A Randomized, Placebo-Controlled Study |
000497 |
Olivier Rascol [France] ; Paolo Barone [Italie] ; Robert A. Hauser [États-Unis] ; Yoshikuni Mizuno [Japon] ; Werner Poewe [Autriche] ; Anthony H. V. Schapira [Royaume-Uni] ; Laurence Salin [France] ; Mandy Sohr [Allemagne] ; Catherine Debieuvre [France] | Efficacy, Safety, and Tolerability of Overnight Switching from Immediate- to Once Daily Extended-Release Pramipexole in Early Parkinson's Disease |
000854 |
Björn Holmberg [Suède] ; Jan-Ove Johansson [Suède] ; Werner Poewe [Autriche] ; Gregor Wenning [Autriche] ; Niall P. Quinn [Royaume-Uni] ; Chris Mathias [Royaume-Uni] ; Eduardo Tolosa [Espagne] ; Adriana Cardozo [Espagne] ; Nil Dizdar [Suède] ; Olivier Rascol [France] ; Tarik Slaoui [France] | Safety and tolerability of growth hormone therapy in multiple system atrophy : A double-blind, placebo-controlled study |
000C13 |
Jan C. M. Zijlmans [Royaume-Uni, Pays-Bas] ; Berengere Debilly [France] ; Olivier Rascol [France] ; Andrew J. Lees [Royaume-Uni] ; Franck Durif [France] | Safety of entacapone and apomorphine coadministration in levodopa-treated Parkinson's disease patients: Pharmacokinetic and pharmacodynamic results of a multicenter, double-blind, placebo-controlled, cross-over study |